Haemonetics (STU:HAZ) Other Current Receivables: €0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HAZ Haemonetics Corp STU:HAZ
30 GF Score
Price €68.00
GF Value €74.36
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Haemonetics Other Current Receivables?

Haemonetics STU:HAZ 30 Other Current Receivables is €0 Mil as of Mar. 2026. GuruFocus rates STU:HAZ with a GF Score™ of 30/100 and a GF Value™ of €74.36 (Fairly Valued). The stock has 5 warning signs investors should review.

Haemonetics's Other Current Receivables for the quarter that ended in Mar. 2026 was €0 Mil.


Haemonetics Other Current Receivables Related Terms


Haemonetics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Haemonetics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Other Current Receivables Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Haemonetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:HAZ
30GF Score
Haemonetics Corp STU:HAZ
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0 Mil mean?
Haemonetics (STU:HAZ) has a Other Current Receivables of €0 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Haemonetics and its competitors.
Is Haemonetics' Other Current Receivables too high?
Haemonetics' current Other Current Receivables is €0 Mil. Overall, Haemonetics has a GF Score™ of 30/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Other Current Receivables compare to ITGR and IRTC?
Haemonetics' Other Current Receivables of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Haemonetics and its competitors. Haemonetics's current Other Current Receivables is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (STU:HAZ) is currently considered Fairly Valued. The stock's GF Value™ is €74.36, compared to a current price of €68.00 — trading 8.6% below its estimated fair value. The current Other Current Receivables is €0 Mil. Haemonetics' overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Other Current Receivables is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €68.00 is trading 8.6% below its estimated GF Value™ of €74.36. GuruFocus considers Haemonetics to be Fairly Valued.

Key valuation signals for STU:HAZ:

  • Other Current Receivables: €0 Mil
  • GF Value™: €74.36 vs. price of €68.00 (8.6% below fair value)
  • GF Score™: 30/100 with 5 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
30GF Score

Get the complete analysis for STU:HAZ

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€68.00
Price
€74.36
GF Value